ClinicalTrials.gg
CompletedNCT05042206Updated Sep 25, 2026

Phase 1 Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Chronic Kidney Disease

A Phase 1 interventional study of Cellgram-CKD in Chronic Kidney Disease, sponsored by Pharmicell Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Pharmicell Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Updated Sep 25, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of — 18 open to participants now, 30 under way, 17 of them phase 3. Renal Insufficiency, Chronic · Korea, Republic of.

Enrollment
96th of 101
10 · median 351
Started
2021
with 7 others
Phase 1
3 of 124
none open now
Registered
78th of 124
by date

Among the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, this one is the 96th largest by enrollment of the 101 interventional ones that give a count, is one of 8 that started in 2021, is one of 3 in phase 1, and was the 78th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

18 of the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety of Cellgram-CKD in patients with chronic kidney disease over 12 months after three administrations. The main question it aims to answer is:

- What medical problems do participants have after receiving Cellgram-CKD?

Participants will:

- Receive Cellgram-CKD by intravenous infusion three times at 2-week intervals. Visit the clinic 1, 3, 6, 9, and 12 months after the third administration for safety assessments.

Read the detailed description

The screening test is performed after the clinical trial subject consents in writing to participate in the clinical trial. Subjects who meet the inclusion/exclusion criteria are registered in the clinical trial, and Cellgram-CKD is injected intravenously by puncturing a vein with a needle. After injecting Cellgram-CKD three times at an interval of 2 weeks (14 days), the subject visits the testing institution at 1 month, 3 months, 6 months, 9 months and 12 months for safety evaluation. However, since the safety of Cellgram-CKD has not been established, proceed as follows. In the first 3 subjects who received the investigational product, if no adverse events of Grade 3 or higher according to the NCI-CTCAE related to the investigational product occur 14 days after the 1st and 2nd administration, and 1 month after the 3rd administration, the remaining subjects were sequentially treated. Register as a member and conduct clinical trials. If an adverse event of Grade 3 or higher according to the NCI-CTCAE standard related to the test drug occurs in two of the first three subjects, the clinical trial is terminated early. is conducted by registering three additional test subjects in the same way as the first. If one or more of the three subjects develops a Grade 3 or higher adverse event related to the investigational product, the clinical trial is terminated early, and the remaining subjects are treated only if all three subjects do not have a Grade 3 or higher adverse reaction related to the investigational product. Register to continue the clinical trial.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Cellgram-CKD
  • Chronic Kidney Disease
  • Mesenchymal Stem Cells
  • Chronic Kidney Disease Stage 3b
  • Chronic Kidney Disease Stage 4
  • Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells
04

Who can participate

The criteria were revised on the registry on Sep 25, 2026. See what changed

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 19 to less than 80 years.
  • Participants diagnosed with Stage 3b or Stage 4 chronic kidney disease (CKD) [ 15-44 mL/min/1.73 m²] within 1 year prior to screening.
  • Participants who voluntarily agree to participate in the clinical trial and provide written .

Exclusion criteria

Exclusion Criteria:

  • Those with severe cardiovascular disease (angina, myocardial infarction, unstable arrhythmia, heart failure, etc.) at the screening visit
  • Those with the following medical history/comorbidities A. Gentamicin reaction B. Solid cancer or malignant blood disease within 5 years prior to screening C. cognitive disorder, dementia or psychiatric disorder D. Alcohol or drug abuse E. Severe respiratory disease (, asthma, pneumonia, pulmonary embolism, pneumothorax, etc.) F. Stroke G. Systemic disease
  • Those whose test results fall under the following at the screening visit A. Pathogenic microorganism test (Hbs Ag, Ab, Ab, Syphilis) positive B. Uncontrolled hypertension (systolic blood pressure >190 mmHg or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure \<90 mmHg or diastolic blood pressure \<50 mmHg) C. and ALT ≥ x 3.0 D. Total ≥ upper limit of normal x 1.5
  • At screening, those who have the following treatment history A. Those who are being treated for severe systemic infection B. Those who have been treated with within 28 days prior to screening
  • Those with a history of renal transplantation
  • Those who have received dialysis within 3 months prior to the screening visit or who are planning to undergo dialysis during the clinical trial period
  • Pregnant, lactating, or planning during clinical trials
  • Those who do not agree to comply with the method specified in this protocol during the clinical trial period
  • Those who are receiving drugs that are expected to affect the results of this clinical trial when judged by the investigator
  • Those who participated in other interventional clinical trials within 4 weeks prior to the screening visit and received products/medical devices for investigational use or received procedures
  • Those who have or are planning to administer other cell therapy products
  • Those who are judged by the investigator to be inappropriate to participate in this clinical trial
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Cellgram-CKD

    Participants receive 5 × 10\^7 allogeneic bone marrow-derived mesenchymal stem cells (10 mL) by intravenous infusion three times at 2-week (14-day) intervals.

    Biological: Cellgram-CKD

Interventions

  • BiologicalCellgram-CKD

    5 × 10\^7 allogeneic bone marrow-derived mesenchymal stem cells (10 mL) administered by intravenous infusion three times at 2-week (14-day) intervals.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.

    Time frame: From the first administration of the investigational product to 12 months after the third administration of the investigational product.

Secondary outcomes

  1. Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline

    The change in estimated glomerular filtration rate (eGFR) from baseline will be assessed at 1, 3, 6, 9, and 12 months after administration of the investigational product.

    Time frame: 1, 3, 6, 9, and 12 months after administration of the investigational product.

  2. Change in Blood Urea Nitrogen (BUN) and Creatinine From Baseline

    The changes in blood urea nitrogen (BUN) and creatinine from baseline will be assessed at 1, 3, 6, 9, and 12 months after administration of the investigational product.

    Time frame: 1, 3, 6, 9, and 12 months after administration of the investigational product.

07

Study locations

1 site
  • Asan Medical Center
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2023, 21 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 21 months is above that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Sep 13, 2021
StartActual
Nov 24, 2021
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Male or female between the ages of 19 and 79Now Male or female participants aged 19 to less than 80 years.
  • EditedThoseParticipants diagnosed with CKD stageStage 3b or Stage 4 chronic kidney disease (CKD) [eGFR 15 - 44 mlmL/min/1.73 m2m²] within 1 year beforeprior to screening.
  • EditedThoseParticipants who voluntarily participatedagree to participate in the clinical trial and signed the Informedprovide written informed consent form.
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)Now Incidence of Adverse Events (AEs)Time frame: Adverse events are collected from the first administration of the investigational product to 12 months after the third administration of the investigational product. → From the first administration of the investigational product to 12 months after the third administration of the investigational product.
Sep 25, 2026
Secondary outcomes
2 added, 3 removed
What changed in the outcomes
  • AddedChange in Estimated Glomerular Filtration Rate (eGFR) From BaselineTime frame: 1, 3, 6, 9, and 12 months after administration of the investigational product.
  • AddedChange in Blood Urea Nitrogen (BUN) and Creatinine From BaselineTime frame: 1, 3, 6, 9, and 12 months after administration of the investigational product.
  • RemovedChanges in eGFRTime frame: 1, 3, 6, 9, and 12 months of administration of the investigational product
  • RemovedChanges in BUNTime frame: 1, 3, 6, 9, and 12 months of administration of the investigational product
  • RemovedChanges in CreatinineTime frame: 1, 3, 6, 9, and 12 months of administration of the investigational product
Sep 25, 2026
Title
Clinical Trial to Evaluate SafetyPhase 1 Study of Allogeneic Bone Marrow -Derived Mesenchymal Stem CellCells in Chronic Kidney Disease
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Eligibility 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Male or female between the ages of 19 and 79Now Male or female participants aged 19 to less than 80 years.
    • EditedThoseParticipants diagnosed with CKD stageStage 3b or Stage 4 chronic kidney disease (CKD) [eGFR 15 - 44 mlmL/min/1.73 m2m²] within 1 year beforeprior to screening.
    • EditedThoseParticipants who voluntarily participatedagree to participate in the clinical trial and signed the Informedprovide written informed consent form.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)Now Incidence of Adverse Events (AEs)Time frame: Adverse events are collected from the first administration of the investigational product to 12 months after the third administration of the investigational product. → From the first administration of the investigational product to 12 months after the third administration of the investigational product.
    Secondary outcomes 2 added, 3 removed
    What changed in the outcomes
    • AddedChange in Estimated Glomerular Filtration Rate (eGFR) From BaselineTime frame: 1, 3, 6, 9, and 12 months after administration of the investigational product.
    • AddedChange in Blood Urea Nitrogen (BUN) and Creatinine From BaselineTime frame: 1, 3, 6, 9, and 12 months after administration of the investigational product.
    • RemovedChanges in eGFRTime frame: 1, 3, 6, 9, and 12 months of administration of the investigational product
    • RemovedChanges in BUNTime frame: 1, 3, 6, 9, and 12 months of administration of the investigational product
    • RemovedChanges in CreatinineTime frame: 1, 3, 6, 9, and 12 months of administration of the investigational product
    Title Clinical Trial to Evaluate SafetyPhase 1 Study of Allogeneic Bone Marrow -Derived Mesenchymal Stem CellCells in Chronic Kidney Disease
    + 6 other changes: verification date, description, conditions, arm descriptions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05042206
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Nov 24, 2021
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update
Sep 25, 2026

Study contacts

Kim Hyosang
principal investigator · Asan Medical Center Nephrology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion